Rosuvastatin Reduces the Levels of leptin, IL-8, CRP and TNF-α in Sputum of Patients with Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD) associated acute hypercapnic respiratory failure (AHRF)
Objective: To investigate the effect of rosuvstatin on leptin, IL-8, CRP and TNF-α in sputum in patients with AECOPD associated acute hypercapnic respiratory failure (AHRF). Methods: Forty patients with AECOPD associated AHRF were randomly divided into 2 groups (n=20), rosuvstatin+regular treatment group and regular treatment group. Twenty non-COPD patients were included as control group. To evaluate the severity of AHRF, arterial blood gas (ABG) was obtained and PH, PO2 and PCO2 were measured. Total cells and neutrophils in sputum were evaluated. CRP in sputum was measured by nephelometry. Meanwhile, ELISA was used to analysis leptin, TNF-α and IL-8 in sputum. Results: After treatments, PH, PO2 and PCO2 in patients with AHRF were improved (P<0.05 in all). Meanwhile, there was no significant difference between 2 groups (P>0.05 in all). Total cells and neutrophils in sputum were decreased and the sputum levels of leptin, CRP, TNF-α and IL-8 were attenuated after treatments (P<0.05 in all). However, after 48h treatment, total cells, neutrophils, leptin, CRP, TNF-α and IL-8 in sputum in rosuvstatin+regular treatment group were higher than regular treatment group (P<0.05 in all). Conclusions:Our results demonstrated that rosuvastatin may be an effective drug in COPD treatment. However, more multiple center and wild scale studies should be applied to identify the value of statins in the treatment of COPD.
NETL
NSTL
万方数据
